메뉴 건너뛰기




Volumn 14, Issue 1, 2016, Pages 58-64

Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents

(24)  Axelrad, Jordan a,b   Bernheim, Oren a   Colombel, Jean Frederic a   Malerba, Stefano a   Ananthakrishnan, Ashwin c,l   Yajnik, Vijay c,l   Hoffman, Gila d   Agrawal, Manasi e   Lukin, Dana e   Desai, Amit f   McEachern, Elisa g   Bosworth, Brian f   Scherl, Ellen f   Reyes, Andre h   Zaidi, Hina i   Mudireddy, Prashant j   DiCaprio, David j   Sultan, Keith i   Korelitz, Burton j   Wang, Erwin k   more..


Author keywords

Crohn's Disease; Drug; Tumor; Ulcerative Colitis

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

EID: 84958841167     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.07.037     Document Type: Article
Times cited : (92)

References (27)
  • 1
    • 77950988234 scopus 로고    scopus 로고
    • Infliximab, azathioprine, or combination therapy for crohn's disease
    • Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for crohn's disease. N Engl J Med 2010, 362:1383-1395.
    • (2010) N Engl J Med , vol.362 , pp. 1383-1395
    • Colombel, J.F.1    Sandborn, W.J.2    Reinisch, W.3
  • 2
    • 80455139421 scopus 로고    scopus 로고
    • Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial
    • Panccione R., Ghosh S., Middleton S., et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial. Gastroenterology 2011, 140:S-134.
    • (2011) Gastroenterology , vol.140 , pp. S-134
    • Panccione, R.1    Ghosh, S.2    Middleton, S.3
  • 3
    • 84885618122 scopus 로고    scopus 로고
    • The management of immunosuppression in patients with inflammatory bowel disease and cancer
    • Bernheim O., Colombel J.F., Ullman T.A., et al. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013, 62:1523-1528.
    • (2013) Gut , vol.62 , pp. 1523-1528
    • Bernheim, O.1    Colombel, J.F.2    Ullman, T.A.3
  • 4
    • 33748987908 scopus 로고    scopus 로고
    • Cancer despite immunosurveillance: immunoselection and immunosubversion
    • Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6:715-727.
    • (2006) Nat Rev Immunol , vol.6 , pp. 715-727
    • Zitvogel, L.1    Tesniere, A.2    Kroemer, G.3
  • 5
    • 56949101640 scopus 로고    scopus 로고
    • Immune escape by epstein-barr virus associated malignancies
    • Munz C., Moormann A. Immune escape by epstein-barr virus associated malignancies. Semin Cancer Biol 2008, 18:381-387.
    • (2008) Semin Cancer Biol , vol.18 , pp. 381-387
    • Munz, C.1    Moormann, A.2
  • 6
    • 24944519200 scopus 로고    scopus 로고
    • Azathioprine and UVA light generate mutagenic oxidative DNA damage
    • O'Donovan P., Perrett C.M., Zhang X., et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005, 309:1871-1874.
    • (2005) Science , vol.309 , pp. 1871-1874
    • O'Donovan, P.1    Perrett, C.M.2    Zhang, X.3
  • 7
    • 84857801058 scopus 로고    scopus 로고
    • Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?
    • Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?. Gut 2012, 61:476-483.
    • (2012) Gut , vol.61 , pp. 476-483
    • Beaugerie, L.1
  • 8
    • 0842281645 scopus 로고    scopus 로고
    • Cell death: critical control points
    • Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
    • (2004) Cell , vol.116 , pp. 205-219
    • Danial, N.N.1    Korsmeyer, S.J.2
  • 9
    • 0034641918 scopus 로고    scopus 로고
    • The biochemistry of apoptosis
    • Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
    • (2000) Nature , vol.407 , pp. 770-776
    • Hengartner, M.O.1
  • 10
    • 67349162130 scopus 로고    scopus 로고
    • Tumour necrosis factor and cancer
    • Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9:361-371.
    • (2009) Nat Rev Cancer , vol.9 , pp. 361-371
    • Balkwill, F.1
  • 11
    • 0034764110 scopus 로고    scopus 로고
    • Inflammatory bowel disease is not associated with an increased risk of lymphoma
    • Lewis J.D., Bilker W.B., Brensinger C., et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001, 121:1080-1087.
    • (2001) Gastroenterology , vol.121 , pp. 1080-1087
    • Lewis, J.D.1    Bilker, W.B.2    Brensinger, C.3
  • 12
    • 0032754121 scopus 로고    scopus 로고
    • Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine
    • Korelitz B.I., Mirsky F.J., Fleisher M.R., et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999, 94:3248-3253.
    • (1999) Am J Gastroenterol , vol.94 , pp. 3248-3253
    • Korelitz, B.I.1    Mirsky, F.J.2    Fleisher, M.R.3
  • 13
    • 0033795223 scopus 로고    scopus 로고
    • Increased incidence of non-hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
    • Farrell R.J., Ang Y., Kileen P., et al. Increased incidence of non-hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000, 47:514-519.
    • (2000) Gut , vol.47 , pp. 514-519
    • Farrell, R.J.1    Ang, Y.2    Kileen, P.3
  • 14
    • 78650239266 scopus 로고    scopus 로고
    • A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease
    • Kotlyar D.S., Osterman M.T., Diamond R.H., et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9:36-41.e1.
    • (2011) Clin Gastroenterol Hepatol , vol.9 , pp. 36-41.e1
    • Kotlyar, D.S.1    Osterman, M.T.2    Diamond, R.H.3
  • 15
    • 77349117814 scopus 로고    scopus 로고
    • Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease
    • Long M.D., Herfarth H.H., Pipkin C.A., et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010, 8:268-274.
    • (2010) Clin Gastroenterol Hepatol , vol.8 , pp. 268-274
    • Long, M.D.1    Herfarth, H.H.2    Pipkin, C.A.3
  • 16
    • 84864225717 scopus 로고    scopus 로고
    • Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease
    • Long M.D., Martin C.F., Pipkin C.A., et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012, 143:390-399.
    • (2012) Gastroenterology , vol.143 , pp. 390-399
    • Long, M.D.1    Martin, C.F.2    Pipkin, C.A.3
  • 17
    • 80054862378 scopus 로고    scopus 로고
    • Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease
    • e1-e5
    • Peyrin-Biroulet L., Khosrotehrani K., Carrat F., et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011, 141:1621-1628. e1-e5.
    • (2011) Gastroenterology , vol.141 , pp. 1621-1628
    • Peyrin-Biroulet, L.1    Khosrotehrani, K.2    Carrat, F.3
  • 18
    • 77954426838 scopus 로고    scopus 로고
    • Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study
    • Armstrong R.G., West J., Card T.R. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010, 105:1604-1609.
    • (2010) Am J Gastroenterol , vol.105 , pp. 1604-1609
    • Armstrong, R.G.1    West, J.2    Card, T.R.3
  • 19
    • 22644446331 scopus 로고    scopus 로고
    • Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
    • Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121-1125.
    • (2005) Gut , vol.54 , pp. 1121-1125
    • Kandiel, A.1    Fraser, A.G.2    Korelitz, B.I.3
  • 20
    • 42449097149 scopus 로고    scopus 로고
    • Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study
    • Sogaard K.K., Cronin-Fenton D.P., Pedersen L., et al. Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 2008, 14:519-525.
    • (2008) Inflamm Bowel Dis , vol.14 , pp. 519-525
    • Sogaard, K.K.1    Cronin-Fenton, D.P.2    Pedersen, L.3
  • 21
    • 84905581315 scopus 로고    scopus 로고
    • Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer
    • Beaugerie L., Carrat F., Colombel J.F., et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014, 63:1416-1423.
    • (2014) Gut , vol.63 , pp. 1416-1423
    • Beaugerie, L.1    Carrat, F.2    Colombel, J.F.3
  • 22
    • 0027412956 scopus 로고
    • The effect of immunosuppression on pre-existing cancers
    • Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993, 55:742-747.
    • (1993) Transplantation , vol.55 , pp. 742-747
    • Penn, I.1
  • 23
    • 77953103015 scopus 로고    scopus 로고
    • Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the british society for rheumatology biologics register
    • Dixon W.G., Watson K.D., Lunt M., et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the british society for rheumatology biologics register. Arthritis Care Res (Hoboken) 2010, 62:755-763.
    • (2010) Arthritis Care Res (Hoboken) , vol.62 , pp. 755-763
    • Dixon, W.G.1    Watson, K.D.2    Lunt, M.3
  • 24
    • 77955479672 scopus 로고    scopus 로고
    • Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the german biologics register RABBIT
    • Strangfeld A., Hierse F., Rau R., et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the german biologics register RABBIT. Arthritis Res Ther 2010, 12:R5.
    • (2010) Arthritis Res Ther , vol.12 , pp. R5
    • Strangfeld, A.1    Hierse, F.2    Rau, R.3
  • 25
    • 34249908092 scopus 로고    scopus 로고
    • Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review
    • Gutierrez-Dalmau A., Campistol J.M. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007, 67:1167-1198.
    • (2007) Drugs , vol.67 , pp. 1167-1198
    • Gutierrez-Dalmau, A.1    Campistol, J.M.2
  • 26
    • 84904466334 scopus 로고    scopus 로고
    • Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease
    • Rajca S., Seksik P., Bourrier A., et al. Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. J Crohns Colitis 2014, 8:819-824.
    • (2014) J Crohns Colitis , vol.8 , pp. 819-824
    • Rajca, S.1    Seksik, P.2    Bourrier, A.3
  • 27
    • 84865312684 scopus 로고    scopus 로고
    • Effects of cancer treatment on inflammatory bowel disease remission and reactivation
    • Axelrad J.E., Fowler S.A., Friedman S., et al. Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin Gastroenterol Hepatol 2012, 10:1021-1027.
    • (2012) Clin Gastroenterol Hepatol , vol.10 , pp. 1021-1027
    • Axelrad, J.E.1    Fowler, S.A.2    Friedman, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.